Christopher Ogden - Mar 18, 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol
CTMX
Transactions as of
Mar 18, 2025
Transactions value $
-$5,122
Form type
4
Date filed
3/20/2025, 04:33 PM
Previous filing
Feb 6, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Sale -$5.12K -8.55K -4.08% $0.60 201K Mar 18, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2 Includes 155,821 RSUs.